News
TMDX
75.04
+2.38%
1.75
TransMedics Group (TMDX) Investor Presentation - Slideshow
Seeking Alpha · 03/10 12:31
TransMedics: Triple-Digit Revenue Growth Supports Repricing In FY 2023
Seeking Alpha · 03/03 18:23
Insider Sell: Transmedics Group
Insider Sell: Transmedics Group
MT Newswires · 03/02 17:18
TransMedics: Organ Care System Momentum Keeps Us Bullish
Seeking Alpha · 03/02 00:55
TransMedics: Impressive Performance Continues
Seeking Alpha · 03/01 21:01
Insiders Selling TransMedics Group And 2 Other Stocks
Benzinga · 02/28 13:07
Pre-market Movers: DRCT, VRCA, RVMD, MNPR, AHCO…
NASDAQ · 02/28 11:46
Insider Sell: TransMedics Group
Insider Sell: TransMedics Group
MT Newswires · 02/28 00:57
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), TransMedics Group (TMDX)
TipRanks · 02/27 13:00
TMDX Crosses Above Average Analyst Target
NASDAQ · 02/27 12:38
Is TransMedics a Good Stock to Buy Right Now?
NASDAQ · 02/24 15:40
Why TransMedics Stock Was a Big Star This Week
NASDAQ · 02/24 13:58
Morgan Stanley Remains a Hold on TransMedics Group (TMDX)
TipRanks · 02/23 16:26
TransMedics Group Soars after Earnings and Guidance Beat
TipRanks · 02/23 16:19
Comfort Systems, Gannett, CommScope And Other Big Stocks Moving Higher On Thursday
Benzinga · 02/23 16:15
Cowen & Co. Maintains Outperform on TransMedics Group, Raises Price Target to $75
Benzinga · 02/23 15:28
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $78
Benzinga · 02/23 14:35
JP Morgan Maintains Overweight on TransMedics Group, Raises Price Target to $81
Benzinga · 02/23 14:28
Oppenheimer Maintains Outperform on TransMedics Group, Raises Price Target to $85
Benzinga · 02/23 14:06
Morgan Stanley Maintains Equal-Weight on TransMedics Group, Raises Price Target to $74
Benzinga · 02/23 13:37
More
Webull provides a variety of real-time TMDX stock news. You can receive the latest news about Transmedics Group through multiple platforms. This information may help you make smarter investment decisions.
About TMDX
TransMedics Group, Inc. is a commercial-stage medical technology company. The Company is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed an organ care system (OCS), a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It designed its OCS technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state. It has developed three OCS products, one each for lung, heart and liver transplantation. Its products include OCS Lung, OCS Heart, and OCS Liver. Its OCS product consists of three components customized for each organ, which include the OCS Console, OCS Perfusion Set and OCS Solutions. It is also developing OCS products for additional organs, including kidneys.